Iovance Biotherapeutics (IOVA) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 411.2%.
| ASSET | % RETURN |
|---|---|
Iovance Biotherapeutics (IOVA) | 411.15% |
Twist Bioscience (TWST) | 366.94% |
10X Genomics (TXG) | 348.19% |
MaxLinear (MXL) | 342.06% |
Erasca (ERAS) | 296.23% |
Abcellera Biologics (ABCL) | 261.7% |
AXT (AXTI) | 258.08% |
CareDx (CDNA) | 243.37% |
Aehr Test Systems (AEHR) | 240.1% |
Penguin Solutions (PENG) | 239.99% |
Okeanis Eco Tankers (ECO) | 239.77% |
Pulse Biosciences (PLSE) | 234.92% |
Veradermics (MANE) | 233.74% |
Calumet Specialty Products Partners (CLMT) | 191% |
Kodiak Sciences (KOD) | 190.54% |
International Seaways (INSW) | 182.43% |
Delek US Energy (DK) | 170.63% |
Hyperliquid Strategies Inc Common Stock (PURR) | 168.27% |
Sellas Life Sciences (SLS) | 166.97% |
Iridium Communications (IRDM) | 164.58% |
Ringcentral (RNG) | 160.79% |
Definium Therapeutics (DFTX) | 153.63% |
Enliven Therapeutics (ELVN) | 153.42% |
Oruka Therapeutics (ORKA) | 152.99% |
CVR Energy (CVI) | 152.05% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.